KC Reporter

GLP-1 receptor agonists, specifically tirzepatide and semaglutide, have been linked to potential benefits in reducing addictive behaviors. A new observational study published in Progress in Cardiovascular Diseases highlights these findings. The study suggests that these medications can decrease food cravings, recreational drug use, alcohol consumption, and potentially other addictions.

James O’Keefe, MD, a co-investigator of the study and director of preventive cardiology at Saint Luke’s Mid America Heart Institute, stated: “Today, 73% of American adults are obese or overweight, and the death rate from substance use including alcohol and recreational drugs is twice as high in the U.S. as the next highest nation.” He added that these issues have contributed to a decline in life expectancy over the past decade.

The research analyzed data from randomized clinical trials and systematic analyses of social media focusing on tirzepatide (known as Mounjaro for diabetes and Zepbound for weight loss) and semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss). Meta-analyses indicated that these drugs could improve life expectancy by reducing risks associated with cardiovascular diseases such as heart attack and stroke. They also showed potential in alleviating arthritis pain.

Tirzepatide is noted as the only FDA-approved medication for treating obstructive sleep apnea. Furthermore, GLP-1s are being studied for their potential role in decreasing risks related to neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Dr. O’Keefe remarked: “By modulating dopamine signaling, GLP-1s reduce cravings and allow individuals to be more rational when faced with various temptations in 21st century America.” He emphasized their possible effectiveness against addictions to ultra-processed foods, sweetened drinks, alcoholic beverages, nicotine, methamphetamine, or marijuana.

For further details on this study's findings, readers are encouraged to consult the full article available in Progress in Cardiovascular Disease.